Immunome Stock Analysis

The new indifference towards the small price fluctuations of Immunome may raise some interest from stakeholders. The stock closed today at a share price of 0.0 on very low momentum in trading volume. The company directors and management did not add any value to Immunome investors in July. However, most investors can still diversify their portfolios with Immunome to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to stakeholders with longer-term investment horizons.
Check out Risk vs Return Analysis.

Search Stock Analysis 

The Immunome stock analysis report makes it easy to digest most publicly released information about Immunome and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Immunome Stock analysis module also helps to analyze the Immunome price relationship with some important fundamental indicators such as market cap and management efficiency.

Immunome Stock Analysis Notes

The company had not issued any dividends in recent years. Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. The company was founded in 2006 and is based in Exton, Pennsylvania. IMNM New operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people. To learn more about Immunome call the company at 610 321 3700 or check out

Immunome Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Immunome's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunome or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Immunome is not yet fully synchronised with the market data
Immunome has some characteristics of a very speculative penny stock
Net Loss for the year was (11.05 M).
Immunome currently holds about 9.79 M in cash with (8.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.47.
Immunome has a frail financial position based on the latest SEC disclosures

Immunome Upcoming and Recent Events

Earnings reports are used by Immunome to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunome previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report11th of August 2021
Next Earnings Report16th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Immunome SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Immunome prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Immunome investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Immunome specific information freely available to individual and institutional investors to make a timely investment decision.
20th of July 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
17th of June 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
1st of June 2021
Submission of Matters to a Vote of Security Holders. Entry into a Material Definitive Agreement
20th of May 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
12th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
26th of April 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
20th of April 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
29th of March 2021
Financial Statements and Exhibits. Regulation FD Disclosure

Immunome Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 117.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunome's market, we take the total number of its shares issued and multiply it by Immunome's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Immunome Profitablity

Immunome's profitability indicators refer to fundamental financial ratios that showcase Immunome's ability to generate income relative to its revenue or operating costs. If, let's say, Immunome is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Immunome's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Immunome's profitability requires more research than a typical breakdown of Immunome's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.72) (0.77) 
Return on Average Equity(6.24) (6.41) 
Return on Invested Capital(10.03) (10.82) 

Management Efficiency

The value of Return on Average Assets is estimated to pull down to -0.77. The value of Return on Average Equity is estimated to pull down to -6.41. Immunome Total Assets are relatively stable at the moment as compared to the past year. The company's current value of Total Assets is estimated at 48.04 Million. Current Assets is expected to hike to about 46.3 M this year, although Tangible Assets Book Value per Share will most likely fall to 10.48. Immunome management efficiency ratios could be used to measure how well immunome manages its routine affairs as well as how well it operates its assets and liabilities.
Last ReportedProjected for 2021
Book Value per Share 12.20  13.16 
Enterprise Value over EBIT(4.50) (4.86) 
Enterprise Value over EBITDA(5.06) (5.46) 
Price to Book Value 2.22  2.21 
Tangible Assets Book Value per Share 13.14  10.48 
Enterprise Value86.3 M85.8 M
Tangible Asset Value44.5 M48 M

Immunome Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunome insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunome's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunome insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunome Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Immunome to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Sync Your Broker Now


Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module
Check out Risk vs Return Analysis. Note that the Immunome information on this page should be used as a complementary analysis to other Immunome's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Tools for Immunome Stock

When running Immunome price analysis, check to measure Immunome's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunome is operating at the current time. Most of Immunome's value examination focuses on studying past and present price action to predict the probability of Immunome's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunome's price. Additionally, you may evaluate how the addition of Immunome to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Bond Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance